CONCORDBIO

Concord Biotech Limited

Fermentation and API-focused pharma company with immunosuppressants and anti-infectives

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

concordbiotech.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹1339.00
Market cap
14,008 Cr
Stock P/E
50.9
P/B
6.95
Dividend yield
0.8%
ROE (FY26)
12.9%
ROCE (FY26)
17.1%
Operating margin (FY26)
27.8%
OCF / EBITDA (FY26)
72.6%
OCF / EBITDA (3Y)
59.5%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Concord Biotech makes fermentation-based active pharmaceutical ingredients (APIs) and finished-dose formulations, selling in India and to export markets; its filings describe the business as manufacturing and trading in pharmaceutical products.

Company snapshot

40thBy market cap

Ranked among 119 companies in Pharmaceuticals.

What we see

Positives
  • ✓Net margin of 24.6% — the business keeps a healthy share of every rupee it earns.
2 more signals from the filings.Sign in free to see them all

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales262 Cr241 Cr319 Cr216 Cr310 Cr244 Cr430 Cr204 Cr247 Cr278 Cr326 Cr257 Cr
Operating expenses (approx.)143 Cr135 Cr185 Cr135 Cr174 Cr146 Cr239 Cr143 Cr159 Cr179 Cr208 Cr175 Cr
EBITDA119 Cr106 Cr134 Cr81 Cr137 Cr98 Cr190 Cr61 Cr88 Cr99 Cr119 Cr82 Cr
OPM %45.4%44.0%42.1%37.7%44.1%40.1%44.3%30.1%35.8%35.6%36.4%32.0%
Other income8 Cr8 Cr11 Cr10 Cr10 Cr15 Cr9 Cr14 Cr13 Cr10 Cr15 Cr13 Cr
Interest0.84 Cr0.50 Cr0.46 Cr0.24 Cr0.10 Cr0.10 Cr0.10 Cr0.06 Cr0.06 Cr0.08 Cr0.08 Cr0.04 Cr
Depreciation13 Cr14 Cr14 Cr13 Cr13 Cr13 Cr15 Cr18 Cr18 Cr19 Cr20 Cr18 Cr
Profit before tax113 Cr103 Cr129 Cr80 Cr130 Cr101 Cr184 Cr59 Cr86 Cr86 Cr114 Cr78 Cr
Tax %25.3%24.8%26.2%25.1%26.5%24.9%23.5%25.0%26.4%26.1%22.4%26.4%
Net profit81 Cr78 Cr95 Cr60 Cr96 Cr76 Cr140 Cr44 Cr63 Cr64 Cr88 Cr58 Cr
EPS (₹)₹7.74₹7.41₹9.08₹5.70₹9.15₹7.26₹13.42₹4.21₹6.03₹6.08₹8.46₹5.52

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales617 Cr713 Cr853 Cr1,017 Cr1,200 Cr1,055 CrSign in free for the trailing twelve months
Operating expenses (approx.)289 Cr440 Cr510 Cr585 Cr694 Cr687 CrSign in free for the trailing twelve months
EBITDA328 Cr273 Cr343 Cr432 Cr506 Cr367 CrSign in free for the trailing twelve months
OPM %53.1%38.3%40.2%42.4%42.2%34.8%Sign in free for the trailing twelve months
Other income14 Cr23 Cr35 Cr34 Cr44 Cr52 CrSign in free for the trailing twelve months
Interest0.67 Cr5 Cr5 Cr3 Cr0.53 Cr0.28 CrSign in free for the trailing twelve months
Depreciation28 Cr50 Cr54 Cr54 Cr54 Cr74 CrSign in free for the trailing twelve months
Profit before tax313 Cr238 Cr322 Cr413 Cr495 Cr345 CrSign in free for the trailing twelve months
Tax %24.9%26.4%25.4%25.3%24.9%24.8%Sign in free for the trailing twelve months
Net profit235 Cr175 Cr240 Cr308 Cr372 Cr259 CrSign in free for the trailing twelve months
EPS (₹)₹22.45₹16.72₹22.95₹29.45₹35.52₹24.78Sign in free for the trailing twelve months
Dividend payout %———23.2%24.6%43.2%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital10 Cr10 Cr10 Cr10 Cr10 Cr10 Cr
Reserves990 Cr1,094 Cr1,280 Cr1,516 Cr1,802 Cr2,007 Cr
Borrowings86 Cr61 Cr31 Cr6 Cr0.38 Cr—
Other liabilities97 Cr149 Cr193 Cr168 Cr221 Cr220 Cr
Total liabilities1,183 Cr1,313 Cr1,514 Cr1,701 Cr2,034 Cr2,235 Cr
Fixed assets (net)538 Cr568 Cr593 Cr572 Cr792 Cr786 Cr
CWIP18 Cr74 Cr173 Cr211 Cr50 Cr78 Cr
Investments141 Cr74 Cr137 Cr246 Cr336 Cr491 Cr
Loans & advances———0 Cr41 Cr0 Cr
Inventories154 Cr195 Cr212 Cr208 Cr240 Cr326 Cr
Trade receivables178 Cr232 Cr274 Cr350 Cr522 Cr460 Cr
Cash & bank5 Cr0.67 Cr3 Cr15 Cr0.90 Cr12 Cr
Other assets149 Cr169 Cr122 Cr99 Cr53 Cr81 Cr
Total assets1,183 Cr1,313 Cr1,514 Cr1,701 Cr2,034 Cr2,235 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity167 Cr207 Cr246 Cr265 Cr245 Cr267 Cr
Cash from investing-195 Cr-112 Cr-158 Cr-155 Cr-160 Cr-143 Cr
Cash from financing31 Cr-100 Cr-85 Cr-99 Cr-99 Cr-113 Cr
Net cash flow3 Cr-4 Cr3 Cr12 Cr-14 Cr11 Cr
Free cash flow (OCF − Capex)-37 Cr52 Cr101 Cr180 Cr133 Cr172 Cr

Ratios

MetricMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %28.9%20.9%24.7%27.1%27.3%17.1%
ROE %23.5%15.9%18.6%20.2%20.5%12.9%
Debtor days105119117125158159
Inventory days426452463411330467
Days payable129192204187156146
Cash conversion cycle402378375350333480
OCF / EBITDA %50.9%75.9%71.7%61.5%48.3%72.6%
OCF / EBITDA % (3 years)——65.7%68.6%59.0%59.5%
Debt / equity0.090.050.020.00410.0002—
Current ratio5.744.083.796.306.177.39
Net debt / EBITDA0.250.220.08-0.02-0.0010-0.03